This company has been marked as potentially delisted and may not be actively trading. Cleveland BioLabs (CBLI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CBLI vs. ARDS, EVLO, STAB, AMPE, CMRA, SYRS, PXMD, EFTR, CALA, and CLVRShould you be buying Cleveland BioLabs stock or one of its competitors? The main competitors of Cleveland BioLabs include Aridis Pharmaceuticals (ARDS), Evelo Biosciences (EVLO), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Syros Pharmaceuticals (SYRS), PaxMedica (PXMD), eFFECTOR Therapeutics (EFTR), Calithera Biosciences (CALA), and Clever Leaves (CLVR). These companies are all part of the "medical" sector. Cleveland BioLabs vs. Its Competitors Aridis Pharmaceuticals Evelo Biosciences Statera Biopharma Ampio Pharmaceuticals Comera Life Sciences Syros Pharmaceuticals PaxMedica eFFECTOR Therapeutics Calithera Biosciences Clever Leaves Cleveland BioLabs (NASDAQ:CBLI) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, institutional ownership, earnings, analyst recommendations, valuation and risk. Does the media favor CBLI or ARDS? In the previous week, Cleveland BioLabs' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Cleveland BioLabs Neutral Aridis Pharmaceuticals Neutral Is CBLI or ARDS more profitable? Aridis Pharmaceuticals' return on equity of 0.00% beat Cleveland BioLabs' return on equity.Company Net Margins Return on Equity Return on Assets Cleveland BioLabsN/A -32.84% -31.29% Aridis Pharmaceuticals N/A N/A N/A Which has preferable earnings & valuation, CBLI or ARDS? Cleveland BioLabs has higher revenue and earnings than Aridis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCleveland BioLabs$260K0.00-$2.40MN/AN/AAridis PharmaceuticalsN/AN/A-$30.37MN/AN/A Which has more risk and volatility, CBLI or ARDS? Cleveland BioLabs has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 38.37, meaning that its share price is 3,737% more volatile than the S&P 500. Do institutionals and insiders have more ownership in CBLI or ARDS? 5.1% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 1.0% of Cleveland BioLabs shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryAridis Pharmaceuticals beats Cleveland BioLabs on 5 of the 7 factors compared between the two stocks. Get Cleveland BioLabs News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBLI vs. The Competition Export to ExcelMetricCleveland BioLabsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3K$1.05B$6.11B$10.56BDividend YieldN/A4.84%5.69%4.75%P/E RatioN/A1.2685.4827.60Price / SalesN/A28.98616.90236.99Price / CashN/A17.6437.9261.55Price / BookN/A7.5213.136.76Net Income-$2.40M-$7.77M$3.30B$275.88M Cleveland BioLabs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLICleveland BioLabsN/AN/AN/AN/A$3K$260K0.004Gap UpARDSAridis PharmaceuticalsN/A$0.00-84.6%N/AN/A$11KN/A0.0030Gap DownEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120Gap DownSTABStatera BiopharmaN/A$0.00flatN/A-50.0%$5KN/A0.0020AMPEAmpio PharmaceuticalsN/A$0.00flatN/A+22.7%$3KN/A0.0020CMRAComera Life SciencesN/AN/AN/AN/A$3K$1.00M0.002SYRSSyros Pharmaceuticals3.7869 of 5 stars$0.00flat$1.00+999,900.0%-99.8%$3K$386K0.00120Gap UpPXMDPaxMedicaN/AN/AN/AN/A$2KN/A0.002EFTReFFECTOR Therapeutics0.0662 of 5 stars$0.00flatN/A-99.5%$1KN/A0.0010CALACalithera BiosciencesN/A$0.00flatN/A-95.0%$0.00N/A0.0060High Trading VolumeCLVRClever Leaves0.2916 of 5 stars$0.00-75.0%N/AN/A$0.00$17.42M0.00560 Related Companies and Tools Related Companies Aridis Pharmaceuticals Alternatives Evelo Biosciences Alternatives Statera Biopharma Alternatives Ampio Pharmaceuticals Alternatives Comera Life Sciences Alternatives Syros Pharmaceuticals Alternatives PaxMedica Alternatives eFFECTOR Therapeutics Alternatives Calithera Biosciences Alternatives Clever Leaves Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CBLI) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
